Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May:81:100904.
doi: 10.1016/j.resmer.2022.100904. Epub 2022 May 4.

Cardiovascular manifestations secondary to COVID-19: A narrative review

C Fauvel  1 , A Trimaille  2 , O Weizman  3 , T Pezel  4 , D Mika  5 , V Waldmann  6 , A Cohen  7 , G Bonnet  8
Affiliations
Review

Cardiovascular manifestations secondary to COVID-19: A narrative review

C Fauvel et al. Respir Med Res. 2022 May.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly, becoming a major threat to global health. In addition to having required the adaptation of healthcare workers for almost 2 years, it has been much talked about, both in the media and among the scientific community. Beyond lung damage and respiratory symptoms, the involvement of the cardiovascular system largely explains COVID-19 morbimortality. In this review, we emphasize that cardiovascular involvement is common and is associated with a worse prognosis, and that earlier detection by physicians should lead to better management. First, direct cardiac involvement will be discussed, in the form of COVID-19 myocarditis, then secondary cardiac involvement, such as myocardial injury, myocardial infarction and arrhythmias, will be considered. Finally, worsening of previous cardiovascular disease as a result of COVID-19 will be examined, as well as long-term COVID-19 effects and cardiovascular complications of COVID-19 vaccines.

Keywords: COVID-19; Cardiovascular system.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no conflicts of interest concerning this article. Dr Fauvel reports grants from Pfizer and consulting fees from Janssen, outside the submitted work. Prof Cohen acknowledges the following without any relationship to the current manuscript: research grant from RESICARD (research nurses); and consultant and lecture fees from the companies Amgen, AstraZeneca, Bayer Pharma, Alliance BMS- Pfizer, Novartis, and Sanofi-Aventis.

Figures

Fig 1
Fig. 1
Central Illustration. Cardiovascular manifestations secondary to COVID-19.Abbreviations: ICU: intensive cardiac unit, LV: left ventricular, CV: cardiovascular.
See this image and copyright information in PMC

References

    1. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. - PMC - PubMed
    1. World Health Organization. Corona- virus disease (COVID-19) outbreak (https://www.who.int).
    1. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8(5):475–481. - PMC - PubMed
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420–422. - PMC - PubMed

Substances